SCHEMBL19280767

SCHEMBL19280767

CCOc1noc(C)c1Br

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.40
HPGD P15428 2/20 0.40
HTR2A P28223 1/20 0.39
HTR2C P28335 1/20 0.39
GAA P10253 1/20 0.37
CHRM3 P20309 3/20 0.37
CHRM2 P08172 1/20 0.36
CHRM4 P08173 1/20 0.36
CHRM5 P08912 1/20 0.36
CHRM1 P11229 1/20 0.36
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
CA9 Q16790 1/20 0.35
BRD4 O60885 2/20 0.35
BRD2 P25440 2/20 0.35
CREBBP Q92793 2/20 0.35
MAPT P10636 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.32
TP53 P04637 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7374475 0.78 HTR2A (0.41) HTR2AHTR2CCHRM3CHRM2CHRM4
SCHEMBL4933992 0.75 HTR2A (0.39) HTR2AHTR2CCHRM3CHRM2CHRM4
SCHEMBL8304514 0.69 BRD4 (0.43) SMN1; SMN2GAABRD4BRD2CREBBP
SCHEMBL14944848 0.67 GRIA1 (0.50) HTR2AHTR2CCA12CA1CA2
SCHEMBL16009946 0.67
SCHEMBL433628 0.64
SCHEMBL7366104 0.64 HTR2A (0.37) HTR2AHTR2CCHRM3CHRM2CHRM4
SCHEMBL22121902 0.64 SMN1; SMN2 (0.55) SMN1; SMN2HPGDGAACA12CA1
SCHEMBL7165046 0.63 HTR2A (0.36) HTR2AHTR2CGAACHRM3CHRM2
SCHEMBL1243206 0.62 GAA (0.51) SMN1; SMN2GAAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021057882-A1 EGFR INHIBITOR, COMPOSITION AND PREPARATION METHOD THEREFOR 贝达药业股份有限公司 2021-04-01 WO disclosed
CN-107108554-B 1-cyclohexyl-2-phenylaminobenzimidazole as MIDH1 inhibitor for treating tumors 德国癌症研究中心 2020-11-06 CN disclosed
EP-3209660-B1 1-CYCLOHEXYL-2-PHENYLAMINOBENZIMIDAZOLES AS MIDH1 INHIBITORS FOR THE TREATMENT OF TUMORS DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS (DE) 2020-06-17 EP disclosed
US-10137110-B2 1-cyclohexyl-2-phenylaminobenzimidazoles as mIDH1 inhibitors for the treatment of tumors BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2018-11-27 US disclosed
US-20170319549-A1 1-CYCLOHEXYL-2-PHENYLAMINOBENZIMIDAZOLES AS MIDH1 INHIBITORS FOR THE TREATMENT OF TUMORS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-11-09 US disclosed
EP-3209660-A1 1-CYCLOHEXYL-2-PHENYLAMINOBENZIMIDAZOLES AS MIDH1 INHIBITORS FOR THE TREATMENT OF TUMORS Bayer Pharma Aktiengesellschaft (DE) 2017-08-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170319549-A1 1-CYCLOHEXYL-2-PHENYLAMINOBENZIMIDAZOLES AS MIDH1 INHIBITORS FOR THE TREATMENT OF TUMORS HRH1, MDN1, MDH1 SMN1; SMN2 1385/4885HPGD 2282/4885HTR2A 3870/4885
US-10137110-B2 1-cyclohexyl-2-phenylaminobenzimidazoles as mIDH1 inhibitors for the treatment of tumors HRH1, MDN1, MDH1 SMN1; SMN2 1385/4885HPGD 2282/4885HTR2A 3870/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.